Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2014 Apr 24;19(4):5448-58.
doi: 10.3390/molecules19045448.

Two ellagic acids isolated from roots of Sanguisorba officinalis L. promote hematopoietic progenitor cell proliferation and megakaryocyte differentiation

Affiliations

Two ellagic acids isolated from roots of Sanguisorba officinalis L. promote hematopoietic progenitor cell proliferation and megakaryocyte differentiation

Xiaoping Gao et al. Molecules. .

Abstract

Using a bioassay-directed chromatographic separation, two ellagic acids were obtained from the ethyl acetate extract of the roots of Sanguisorba officinalis L. On the basis of chemical and spectroscopic methods, the two ellagic acids were identified as 3,3',4-tri-O-methylellagic acid-4'-O-β-d-xyloside and 3,3',4-tri-O-methylellagic acid. Stimulation of cell proliferation was assayed in hematopoietic progenitor cells using the Cell Counting kit-8 method. The megakaryocyte differentiation was determined in human erythroleukemia (HEL) cells using Giemsa staining and flow cytometry analysis. The ellagic acids significantly stimulated the proliferation of Baf3/Mpl cells. Morphology analysis and megakaryocyte specific-marker CD41 staining confirmed that the ellagic acids induced megakaryocyte differentiation in HEL cells. This is the first time that 3,3',4-tri-O-methylellagic acid or 3,3',4-tri-O-methylellagic acid-4'-O-β-d-xyloside are reported to induce megakaryopoiesis, suggesting a class of small molecules which differ from others non-peptidyl, and appears to have potential for clinical development as a therapeutic agent for patients with blood platelet disorders.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Structure of compound 1.
Figure 2
Figure 2
Structure of compound 2.
Figure 3
Figure 3
Compounds promote the proliferation of Baf3/Mpl cells. (A) Compounds 1 and 2 stimulate cell proliferation in a dose-dependent manner. (B) Compounds 1 and 2 stimulate cell proliferation in a time-dependent manner. Results are representative of at least three independent experiments run in triplicate and expressed as the mean ± SD.
Figure 4
Figure 4
Compounds induced megakaryopoiesis in HEL cells. (A) Light microscopy shows that the image of megakarycytes (control and compound 1, left and right respectively) stained by Giemsa; (B) The percentage of megakaryocytes was determined on the basis of the number of endomitosis. Results are representative of at least three independent experiments run in triplicate and expressed as the mean ± SD.
Figure 5
Figure 5
Flow cytometric analysis of HEL cells stained with anti-CD41-PE. Histogram plot (left panel) and dot plot (right panel) show the percentage of CD41+ cells. Data represent one experiment of two independent experiments. (A) Control (DMSO); (B) Compound 1 (20 μg/mL); (C) Compound 2 (20 μg/mL).

References

    1. Vadhan_Raj S., Murray L.J., Bueso-Ramos C., Patel S., Reddy S.P., Hoots W.K., Johnston T., Papadopolous N.E., Hittelman W.N., Johnston D.A., et al. Stimulation of megakaryocyte and platelet production by a single dose of recombinant human thrombopoietin in patients with cancer. Ann. Intern. Med. 1997;126:673–681. doi: 10.7326/0003-4819-126-9-199705010-00001. - DOI - PubMed
    1. Vadhan_Raj S., Verschraegen C.F., Bueso-Ramos C., Broxmeyer H.E., Kudelka A.P., Freedman R.S., Edwards C.L., Gershenson D., Jones D., Ashby M., et al. Recombinant human thrombopoietin attenuates carboplatin-induced severe thrombocytopenia and the need for platlet transfusions in patients with gynecologic cancer. Ann. Intern. Med. 2000;132:364–368. - PubMed
    1. Li J., Yang C., Bertino A., Glaspy J., Roberts M., Kuter D.J. Thrommbocytopenia caused by the development of antibodies to thrombopoietin. Blood. 2001:3241–3248. - PubMed
    1. Basser R.L., O’Flaherty E., Green M., Edmonds M., Nichol J., Menchaca D.M., Cohen B., Begley C.G. Development of pancytopenia with neutralizing antibodies to thrombopoietin after multicycle chemotherapy supported by megakaryocyte growth and development factor. Blood. 2002;99:2599–2602. doi: 10.1182/blood.V99.7.2599. - DOI - PubMed
    1. Nogami W., Yoshida H., Koizumi K., Yamada H., Abe K., Arimura A., Yamane N., Takahashi K., Yamane A., Oda A., et al. The effect of a novel, small non-peptidyl molecule butyzamide on human thrombopoietin receptor and megakaryoopoisis. Haematologica. 2008;93:1495–1504. doi: 10.3324/haematol.12752. - DOI - PubMed

Publication types

MeSH terms